...
首页> 外文期刊>Canadian Respiratory Journal >Association of Metformin Use with Asthma Exacerbation in Patients with Concurrent Asthma and Diabetes: A Systematic Review and Meta-Analysis of Observational Studies
【24h】

Association of Metformin Use with Asthma Exacerbation in Patients with Concurrent Asthma and Diabetes: A Systematic Review and Meta-Analysis of Observational Studies

机译:二甲双胍与哮喘患者哮喘哮喘和糖尿病患者的结合:对观察研究的系统审查和荟萃分析

获取原文

摘要

Background. Asthma and diabetes are both diseases that affect a wide range of people worldwide. As a common treatment for diabetes, metformin has also been reported to be effective in improving asthma outcomes. We conducted a combined analysis to examine the efficacy of metformin in reducing asthma exacerbation in patients with concurrent asthma and diabetes. Methods. We searched the PubMed, Embase, and CENTRAL databases for articles published prior to April 2020 to find observational studies of individuals with concurrent asthma and diabetes that compared the risk of asthma exacerbation between metformin users and nonusers. Two researchers separately screened the studies, extracted data, and evaluated the risk of bias. The primary outcome was the adjusted risk of asthma exacerbation. The secondary outcomes were the adjusted risk of asthma-related hospitalization and emergency room visits. Review Manager was used for data analysis and plotting. I2 and χ2 tests were used to estimate heterogeneity. A random effects or fixed effects model was used depending on the heterogeneity. Odds ratios were calculated for dichotomous variables. Results. We included two studies with a total of 25252 patients. The pooled effect size showed that metformin was inversely associated with a risk of asthma exacerbation (OR?=?0.65, 95% CI 0.28–1.48; χ2?=?5.42, P=0.02; I2?=?82%), asthma-related emergency department visits (OR?=?0.81, 95% CI 0.74–0.89; χ2?=?0.36, P=0.55; I2?=?0%), and hospitalizations (OR?=?0.43, 95% CI 0.14–1.29; χ2?=?4.01, P=0.05; I2?=?75%). Conclusion. This meta-analysis suggested that metformin decreased the risk of asthma-related emergency room visits for patients with concurrent asthma and diabetes. Metformin reduced the risk of asthma-related hospitalization and exacerbation but was not statistically significant. More randomized trials involving larger samples should be considered, and the mechanisms of these effects need to be fully elucidated.
机译:背景。哮喘和糖尿病是影响全世界广泛的疾病。作为糖尿病的常见治疗,据报道,二甲双胍也有效改善哮喘结果。我们进行了组合分析,以检查二甲双胍在减少同时哮喘和糖尿病患者哮喘恶化的疗效。方法。我们在2020年4月2020年之前搜索了PubMed,Embase和Central数据库,以寻找具有同时哮喘和糖尿病的个体的观察性研究,比较了二甲双胍用户和非用户之间的哮喘恶化的风险。两位研究人员分别筛选了研究,提取数据,并评估了偏倚的风险。主要结果是哮喘加剧的调整风险。二次结果是哮喘相关住院和急诊室访问的调整风险。审查经理用于数据分析和绘图。 I2和χ2试验用于估计异质性。根据异质性使用随机效应或固定效果模型。计算二分法变量的差距。结果。我们包括两项研究,共有25252名患者。汇集的效果大小表明,二甲双胍与哮喘加剧的风险与哮喘的风险(或α= 0.65,95%CI 0.28-1.48;χ2?5.42,P = 0.02; I2?=?82%),哮喘 - 相关的急诊部门访问(或?=?= 0.81,95%CI 0.74-0.89;χ2?= 0.36,p = 0.55; I2?= 0%)和住院(或?=?0.43,95%CI 0.14- 1.29;χ2?=?4.01,P = 0.05; I2?=?75%)。结论。该荟萃分析表明,二甲双胍对哮喘和糖尿病患者患者的哮喘相关急诊室访问的风险降低。二甲双胍降低了哮喘相关住院和加剧的风险,但没有统计学意义。应考虑涉及较大样品的更多随机试验,并且需要完全阐明这些效应的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号